Join

Compare · AZN vs FWP

AZN vs FWP

Side-by-side comparison of AstraZeneca PLC (AZN) and Forward Pharma A/S (FWP): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AZN and FWP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • AZN is the larger of the two at $263.07B, about 4842.3x FWP ($54.3M).
  • AZN has hit the wire 11 times in the past 4 weeks while FWP has been quiet.
  • AZN has more recent analyst coverage (25 ratings vs 0 for FWP).
MetricAZNFWP
Company
AstraZeneca PLC
Forward Pharma A/S
Price
$169.61-1.03%
$1.95+0.00%
Market cap
$263.07B
$54.3M
1M return
-7.79%
-
1Y return
-9.92%
-
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2026
2014
News (4w)
11
0
Recent ratings
25
0
AZN

AstraZeneca PLC

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

FWP

Forward Pharma A/S

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. The company was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

Latest AZN

Latest FWP